Sergio Contreras

This worries me. AI can only become better and better to fool us all. We lead by trust + integrity; we need more than ever better tools + accountability. This even passed @NEJM before being retracted….kudos to @NEJM editors for catching this shortly! nejm.org/doi/full/10.10…

Super excited that the @CUCancerCenter now has a webpage highlighting how we care for older adults with cancer! Personalized, multidisciplinary, and focused on what matters most to patients 💪 Check it out 👇 medschool.cuanschutz.edu/colorado-cance…

“Did pandemics truly change pulmonary embolism rates in oncology patients—or are we seeing reference bias and hidden collateral effects behind these uneven proportions?” doi.org/10.1371/journa…

No te lo pierdas incmnsz.mx/Ensenanza/Conv…

Excited to be an #AACR26 ambassador and have the privelege of attending my 11th in person @aacr annual meeting! It’s always an inspiring experience that leaves me refreshed and motivated. 2025- the year of #ecDNA and #KRAS, 2026- #AI and new drug types? @utswcancer

La NCCN agrega modelos de IA para mejorar la predicción del riesgo de CM 🧪 Modelos de IA+MG integrados en la NCCN para análisis automatizado de mastografías. 🚀 Predicción de riesgo a 5 años en Px sin FR 📉 Riesgo ≥ 1.7% = "Riesgo Aumentado" 🔗 La noticia completa aquí: shorturl.at/fQeFQ @DrRagosan @ScienceLinkOnco #CancerDeMama #MedTwitter #Oncologia #NCCN #IA ⛲ shorturl.at/axkMg

Le envío una felicitación muy especial al Dr. Alberto Ávila Funes por este merecido reconocimiento. Enhorabuena!

El secretario de Salud, David Kershenobich, y la embajadora del Reino Unido en México, Susannah Goshko, sostuvieron un encuentro para fortalecer la cooperación bilateral en salud, centrada en la modernización del sistema mediante la innovación tecnológica, el fortalecimiento regulatorio y la promoción de oportunidades de inversión en México. 🇬🇧🫱🏽‍🫲🏼🇲🇽 En la reunión participó el subsecretario de Integración Sectorial y Coordinación de Servicios de Atención Médica, Eduardo Clark, así como los titulares del Consejo de Salubridad General, COFEPRIS y CCINSHAE. 🩺

We published in lung cancer a review of respiratory sarcopenia in the area of ​​thoracic oncology. doi.org/10.1016/j.lung… Respiratory sarcopenia is a clinically relevant but incompletely defined. A feasible, strength-first screening can identify patients who may require closer peri-operative attention. Imaging surrogates and diaphragm ultrasound provide additional contextual information when available. While reported associations with complications and survival are suggestive, they are uneven due to heterogeneity in definitions, thresholds, and protocols. Within enhanced recovery pathways, inspiratory muscle training can be considered a component of multimodal optimization for selected patients. We emphasize that careful, claims-disciplined use of RS metrics, as a complement to established risk tools and clinical judgment, is reasonable. Future priorities include harmonizing measurement protocols and deriving thoracic-specific thresholds to determine who benefits most and how best to deploy resources effectively. @detectoincan @incanMX @JordiRemon @MarisolNeumo @JennyTurcott @Ecaballep @LungCancerEu @AndresFCardonaz

Happy to see the poster walks leads for today!! @raymanneh 🇨🇴 @DrRanaMcKay 🇺🇸 Will lead the #kidneycancer discussion @GU26 @ASCO Optimal time ICIS, Genmic dedifferentiation & integrative genomic landscape @OncoAlert @UrologyTimes @jrgralow

LAST DAY!! #GU26 @asco 📅 ⏰Awaiting @katy_beckermann discussion of the LITESPARK studies! starting 8:10 am - Are we going to change treatment sequencing in mRCC? @motzermd - Is there a new standard for adjuvant ccRCC? @DrChoueiri Don´t miss this evvent @Larvol @OncoAlert

DAY3⃣ @asco #GU26 #kidneycancer The BELZUTIFAN story! 🔴LITESPARK-011 Belzu + lenva vs cabo for aRCC after PDL1 🔵LITESPARK-022 Adjuvant pembro+belzu vs pembro in localized ccRCC @DrChoueiri 🟠LITESPARK-024 dose escalation of belzu + palbo #ASCOVoices @OncoAlert @oncodaily

DAY 2: #Urothelialcancer @asco #GU26 🟢 KEYNOTE-B15 EV + pembro cisplatin-eligible MIBC 📢 TOP abstract @MattGalsky 🧑‍🔬 RC48G001 P2 disitamab HER2+ previously tx aUC @tompowles1 🌅 SunRISe-2 Gem-intravesical +cetre vs ChemoRT in MIBC @AndreaNecchi @OncoAlert @oncodaily

Day 1: Prostate 8:15 am @ASCO #GU26 3️⃣ studies w updated OS ✅ PEACE 3: enza w or w/o radium-223 in mCRPC ✅ BRCAway: abi vs Olaparib vs abi+Olaparib mCRPC & DNA repair def ✅ ASCENDE-RT ⏩ 15 years external beam RT boost vs brachy in localized PC @OncoAlert @UrologyTimes

Get to know the #ascovoices #GU25 @ASCO @ConquerCancerFd Follow our experts 📲💻🧑🏼‍⚕️👨🏻‍⚕️👩🏻‍⚕️ They will be summarizing the most important updates in GU Oncology ✅‼️ @OncLive @OncoAlert @UrologyTimes @bergsa83 @OncBrothers @urotoday @Uromigos @oncodaily @PaolaVS94 @BourlonMaite

🗣️🥳Happy to be #ascovoice at this @ASCO #GU26 @ConquerCancerFd I’ll be sharing the latest breakthroughs in GU oncology directly from San Francisco 🌉 Stay tuned & turn on notifications so you don’t miss a single update 🛎️ @OncoAlert @oncodaily @urotoday @UrologyTimes

"Doctors need more time to think" Society must protect thought time in a world of instant communication. The difference between a good and a bad diagnosis lies largely in the doctor's time to reflect, to think, to apply the scientific method. Sorry for paraphrasing this paper.

Este 4 de febrero se conmemora el día mundial contra el cáncer, problema de salud trascendental, con más de 20 millones de nuevos casos diagnosticados anualmente y 10 millones de muertes. En este informe, el Dr Chales M Balch y col, revisan el creciente impacto de la enfermedad, la profunda desigualdad en su tratamiento y las iniciativas para la prevención y detección temprana en la diferentes regiones del mundo, incluyendo LATAM @ecancer @enriquesoto8 @mtzsaid @incanMX @TonyMok9 @incanMX ecancer.org/en/journal/art…

February 4th is World Cancer Day. Join us in spreading the message of global support. Find out how at lnkd.in/emGk7DU Tay tuned for more on how UHN is recognizing World Cancer Day in 2026! #WorldCancerDay #UnitedByUnique @uicc

⚡️ Bladder preservation after neoadjuvant therapy in MIBC: promising, but not ready to routinely supplant radical cystectomy. Evidence still lacks phase 3 noninferiority vs RC, and approaches remain heterogeneous. For now: option for highly selected pts, within expert centres + strict follow-up. #BladderCancer sciencedirect.com/science/articl…